GLP-1 pathway activity may add hair loss risk in men

Clinical takeaway: Watch for persistent or patterned hair loss in genetically susceptible men on GLP-1 agonists, rather than assuming regrowth will follow weight stabilization. Study examines men only, so it's possible this plays a role in women as well.

Patients on GLP-1 receptor agonists have been showing up with thinning hair almost as long as the drugs have been popular, and clinicians have had a reassuring answer ready. The hair seemed to shed faster because the weight came off quickly, and it usually grows back once weight stabilizes. That reassurance assumes every case is telogen effluvium, the diffuse, temporary shedding that follows a physiologic stress and resolves on its own. 

But new research questions if that assumption holds true for everyone. Retrospective cohorts have hinted at a link between GLP-1 receptor agonist exposure and androgenetic alopecia, a patterned, progressive loss that no amount of weight stability reverses. Those studies could not untangle the pathway from everything around it, since every proposed route to the follicle runs through metabolic territory the drugs already occupy. Researchers have now untangled more information on underlying genetics, using Mendelian randomization. This treats inherited genetic variation as a stand-in for lifelong exposure, asking whether GLP-1 receptor pathway activity drives male pattern hair loss. 

The genetics point to the pathway itself as a contributor to pattern hair loss, not just the weight coming off. Men with variants driving higher GLP1R expression had 7% higher odds of male pattern hair loss for each standard deviation increase in predicted expression, with a plausible range of 4% to 9%. The association barely moved under any of the checks the researchers threw at it. It held across five sensitivity analyses and persisted after adjustment for waist-to-hip ratio, systolic blood pressure, insulin-like growth factor 1, and testosterone, whether each was accounted for individually or all at once. Whatever connects the pathway to the follicle, it does not appear to run entirely through those metabolic and hormonal routes. 

None of this means the drugs themselves have been shown to cause hair loss. Men who naturally run higher GLP1R expression their whole lives proved more likely to lose their hair, which implicates the pathway the drugs act on without testing what the drugs do to it. Taking a medication for a year or two is not the same exposure as a lifetime of elevated expression, and the authors are careful to claim only that the pathway is involved. A separate exploratory check gave the idea biological footing, confirming that the GLP-1 receptor shows up in human hair follicles and appears more abundant in scalp already losing hair. 

"Our study provides the first genetic link between GLP-1 use and an increased risk of male-pattern hair loss from androgenetic alopecia, an association long suspected but until now not shown scientifically," said study senior investigator Lynn Petukhova, PhD, an assistant professor in the Department of Dermatology and the Department of Population Health at NYU Grossman School of Medicine. 

The researchers built a genetic instrument for GLP1R expression from 22 expression quantitative trait loci in whole blood, drawn from 31,864 people of European ancestry in eQTLGen, and tested it against a male pattern hair loss GWAS of 205,327 men. The primary estimate came from inverse-variance weighted Mendelian randomization, with multivariable models adjusting for candidate mediators. Because no comparable GWAS exists for female pattern hair loss, the analysis was restricted to men. 

Whether pharmacologic GLP-1 exposure mirrors the genetic signal is now the testable question. Hair loss is rarely a prespecified outcome in trials, and adverse event reports tend to blur pattern loss with transient shedding. So, the authors call for hair outcomes to be tracked systematically in GLP-1 trials and registries. Work on the mechanism is also queued up, starting with how GLP-1 receptor signaling behaves in the follicle itself. 

"Our findings suggest that, if future experiments prove successful, some men, and possibly women too, could be screened and benchmarked for their risk of hair loss before being prescribed GLP-1 medications," Petukhova said. "We could also envision these findings leading to some GLP-1 users being prescribed combination treatments to prevent hair loss, such as minoxidil or some other drug." 

Source: Ramessur R, et al. (2026 Sep 3) J Invest Dermatol. A causal effect of increased GLP1R expression on Male Pattern Hair Loss is suggested by Two-Sample Mendelian Randomization